A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
This research study, called RESOLUTE, is looking into a new treatment, SPK-3006, for adults who have late-onset Pompe disease. Pompe disease is a rare condition that affects muscles, and late-onset means it usually develops in adulthood. The study wants to find out if this new medicine is safe and if it can help people's symptoms. All participants will have already been receiving standard enzyme replacement therapy (ERT) for at least two years. The main goal is to check for side effects and see how well the treatment works after a single dose given into the blood. Researchers will start with a small group of people and slowly increase the dose for new groups, all while closely monitoring everyone's health.
Em resumo
Sobre o que é este estudo?
This study is called RESOLUTE and it's looking for new ways to help people with a condition called late-onset Pompe disease. Pompe disease is a rare genetic condition where the body can't properly break down a sugar molecule called glycogen, which then builds up in cells, especially in muscles. This can make muscles weak and cause other health problems. 'Late-onset' means the symptoms usually start during teenage years or adulthood.
Currently, many people with Pompe disease are treated with something called enzyme replacement therapy (ERT). This study is testing an experimental new medicine, SPK-3006, which works differently from ERT. It's a type of 'gene therapy,' which means it aims to help the body make the missing enzyme itself, rather than needing regular infusions of the enzyme from outside the body.
The main goals of this study are to make sure SPK-3006 is safe for people to use and to see if it can improve their symptoms. All participants will receive a single dose of SPK-3006 into their blood. Researchers will then closely monitor their health, how their body reacts to the treatment, and if their Pompe disease symptoms get better over time. They will start with small doses in a few people and gradually increase the dose for new groups, all under careful medical supervision.
Pontos principais
- This study is testing a new gene therapy (SPK-3006) for adults with late-onset Pompe disease.
- It aims to check the safety and potential benefits of a single dose of the medicine.
- Participants must have been on standard ERT for at least two years.
- Close monitoring for side effects and treatment response will be carried out.
- Participation involves regular clinic visits for blood tests and health checks.
Quem pode ser elegível?
To join this study, you need to be an adult (18 years or older) with late-onset Pompe disease. You must have been receiving your usual enzyme replacement therapy (ERT) for at least two years and your condition should be considered 'moderate'. You also need to be able to understand the study and agree to take part in writing. If you can become pregnant, you'll need to agree to use reliable birth control during the study.
There are also some reasons why you might not be able to join. For example, if you have certain other serious health conditions like active hepatitis B or C, significant liver problems, HIV, or a history of liver cancer. You also can't take part if you currently have an active infection, are pregnant or breastfeeding, or if you've had a bad reaction to similar treatments in the past. If you need a breathing machine all the time while awake, or if you've already had gene therapy before, you also wouldn't be able to join.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 18 anos ou mais?
- Do you have late-onset Pompe disease?
- Have you been receiving enzyme replacement therapy (ERT) for at least 2 years?
- Do you have no active serious infections or liver problems?
- Are you able to use reliable birth control if you can become pregnant?
O que envolve a participação?
If you decide to take part in this study, you'll first have some careful checks to make sure you're suitable. Once enrolled, you will receive a single dose of the new medicine, SPK-3006, directly into your blood. After this, you'll have regular visits to the clinic for assessments. These will include blood tests, physical examinations, and tests to see how your muscles and breathing are working. The team will be watching closely for any side effects and how your body responds to the treatment. The total duration of your participation in the study will be determined by how long researchers need to follow up on the effects of the single dose.
Riscos e benefícios potenciais
Localizações (29)
- Barrow Neurological InstituteCódigo postal verificadoPhoenix, Estados Unidos
- University of California Irvine HealthCódigo postal verificadoOrange, Estados Unidos
- Emory University School of MedicineCódigo postal verificadoAtlanta, Estados Unidos
- University of Kansas Medical Center Research InstituteCódigo postal verificadoKansas City, Estados Unidos
- Universidade de MinnesotaCódigo postal verificadoMinneapolis, Estados Unidos
- Oregon Health & Science UniversityCódigo postal verificadoPortland, Estados Unidos
- Universidade da PensilvâniaCódigo postal verificadoFiladélfia, Estados Unidos
- University of Pittsburgh Medical CenterCódigo postal verificadoPittsburgh, Estados Unidos
- University of UtahCódigo postal verificadoSalt Lake City, United States
- Lysosomal and Rare Disorders Research & Treatment CenterCódigo postal verificadoFairfax, United States
- Hospital Geral de VancouverCódigo postal verificadoVancouver, Canadá
- O Hospital de OttawaCódigo postal verificadoOttawa, Canadá
Perguntas frequentes
What is late-onset Pompe disease?
It's a rare genetic condition where your body can't properly break down a sugar called glycogen, causing muscle weakness and other problems, usually starting in adulthood.
What is SPK-3006?
SPK-3006 is an experimental new medicine, a type of gene therapy, being tested to see if it can help the body produce the missing enzyme in Pompe disease.
Will I still take my current medicine if I join?
Yes, you generally need to have been on your usual enzyme replacement therapy (ERT) for at least two years to be considered for this study.
Como o medicamento será administrado?
You will receive a single dose of SPK-3006 directly into your blood, usually through a drip.
Quanto tempo estarei no estudo?
The study involves a single dose of the medicine followed by regular check-ups and monitoring for a period that the research team will explain to you.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.